Apoteket (A) Q2 2026 earnings summary

Executive summary

• Net sales for April–June 2026 increased by 12.9% year-over-year to SEK 7,545 million, driven by a new healthcare contract and higher sales in both physical stores and e-commerce.

• Operating profit for the quarter rose to SEK 183 million, with a stable operating margin of 2.4%.

• Net profit for the quarter reached SEK 202 million, up from SEK 183 million in the same period last year.

• Continued investments in new business areas and physical presence, including new pharmacy openings and upgrades.

• Positive developments in new operations supplying pharmaceuticals to regions and strong results in employee and customer satisfaction surveys.

Financial highlights

• Net sales for January–June 2026 totaled SEK 15,059 million, up 14.9% year-over-year.

• Operating profit for January–June was SEK 311 million, compared to SEK 282 million last year.

• Net profit for January–June was SEK 361 million, up from SEK 334 million.

• Operating cash flow for January–June was SEK 718 million.

• Total assets as of June 30, 2026, were SEK 16,297 million, with equity of SEK 10,140 million.

Outlook and guidance

• Long-term target for operating margin is 3.0%; the rolling 12-month margin was 2.0%.

• Solidarity target is 35–45%; achieved 43.3% as of June 30, 2026.

• Dividend policy is 40–60% of annual profit adjusted for pension effects; dividend of SEK 271 million for 2025 was paid.